|
Company:
|
BIOMX INC. (PHGE)
|
|
Form Type:
|
SC 13G
|
|
Filing Date:
|
11/6/2019
|
|
CIK:
|
0001739174
|
|
Address:
|
17 STATE STREET, 16TH FLOOR
|
|
City, State, Zip:
|
NEW YORK, New York 10004
|
|
Telephone:
|
646-465-9000
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$6.69
|
Change:
0.00 (0.00%)
|
Trade Time:
Jan 14
|
Market Cap:
$155.52M
|
|
|
|
|
|
|
Description of Business
|
|
BiomX is an Israeli company formed on March 3, 2015. It is a clinical stage
microbiome product discovery company developing products using both natural and
engineered phage technologies designed to target and destroy bacteria that
affect the appearance of skin, as well as harmful bacteria in chronic diseases,
such as inflammatory bowel disease ("IBD"), liver disease and cancer.
Bacteriophage or phage are viruses that target bacteria and are considered inert
to mammalian cells. By utilizing proprietary combinations of naturally occurring
phage and by creating novel phage using synthetic biology, BiomX develops
phage-based therapies intended to address large-market and orphan diseases.
|
|
|
|